Literature DB >> 20699181

Endocrinopathic laminitis: reducing the risk through diet and exercise.

Nicola J Menzies-Gow1.   

Abstract

Certain individual animals appear predisposed to recurrent pasture-associated laminitis, but the exact mechanisms underlying their predisposition remain a fundamental question in laminitis research. The risk of endocrinopathic laminitis can be reduced if steps are taken to improve insulin sensitivity and reduce inflammation using strategies based on exercise and diet. Exercise has been shown to reduce insulin resistance and suppress inflammation, and dietary manipulation can significantly affect insulin sensitivity. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20699181     DOI: 10.1016/j.cveq.2010.04.005

Source DB:  PubMed          Journal:  Vet Clin North Am Equine Pract        ISSN: 0749-0739            Impact factor:   1.792


  4 in total

1.  The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies.

Authors:  Alexandra Meier; Dania Reiche; Melody de Laat; Christopher Pollitt; Donald Walsh; Martin Sillence
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

2.  Influence of dietary restriction and low-intensity exercise on weight loss and insulin sensitivity in obese equids.

Authors:  Nicholas J Bamford; Samantha J Potter; Courtnay L Baskerville; Patricia A Harris; Simon R Bailey
Journal:  J Vet Intern Med       Date:  2018-12-05       Impact factor: 3.333

3.  Genome-Wide Association Analyses of Equine Metabolic Syndrome Phenotypes in Welsh Ponies and Morgan Horses.

Authors:  Elaine Norton; Nichol Schultz; Ray Geor; Dianne McFarlane; James Mickelson; Molly McCue
Journal:  Genes (Basel)       Date:  2019-11-06       Impact factor: 4.096

4.  Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.

Authors:  Eleanor M Kellon; Kathleen M Gustafson
Journal:  Open Vet J       Date:  2022-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.